Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single and Multiple-dose Escalation First-in-Human Study Evaluating the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Administered Via Inhalation and IV Infusion in Healthy Subjects and Patients With Mild Asthma.

Next Previous
X
Search
Trial Profile

A Single and Multiple-dose Escalation First-in-Human Study Evaluating the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Administered Via Inhalation and IV Infusion in Healthy Subjects and Patients With Mild Asthma.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LQ 036 (Primary) ; LQ 036 (Primary) ; LQ 036 (Primary)
  • Indications Asthma
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics

    • Most Recent Events

    • 13 Sep 2023 Results assessing ate the safety, tolerance, pharmacokinetics (PK) and systemic IL4R target engagement of LQ036 presented at the 33rd Annual Congress of the European Respiratory Society
    • 24 May 2023 Results presented at the 119th International Conference of the American Thoracic Society
    • 11 Apr 2023 Status changed from recruiting to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top